HOME >> BIOLOGY >> NEWS
Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer

PHILADELPHIA A therapeutic cancer vaccine has shown effectiveness when given alongside chemotherapy to patients with metastatic colorectal cancer in a phase II trial, according to researchers at Oxford BioMedica (UK) Ltd. The study found that six of the 17 metastatic colorectal cancer patients in the study showed tumor shrinkage, classified as complete or partial responses following independent expert review.

The study, reported in the August 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, was designed to demonstrate the safety and immunogenicity of the vaccine, called modified vaccinia Ankara-encoding 5T4 (TroVax), when used alongside standard chemotherapy. The research was funded by Oxford BioMedica which is developing the vaccine in partnership with Sanofi-Aventis.

Unlike preventative vaccines, such as the human papillomavirus vaccine to prevent cervical cancer, TroVax is a therapeutic vaccine, designed to stimulate the immune systems of patients who already have cancer. The vaccine consists of an attenuated (non-disease causing) version of the vaccinia virus modified to deliver the gene for 5T4, a protein found in many tumors.

The idea is that the modified virus enters cells, produces the tumor protein and stimulates the immune system, said lead study author Richard Harrop, Ph.D., vice president of clinical immunology at Oxford BioMedica. To give a vaccine alongside chemotherapy might seem counterintuitive, since chemotherapy can weaken the immune system, but our study shows that TroVax could be complementary to standard chemotherapy, enhancing the immune response to tumors.

The target of this immuno-therapy approach is a tumor antigen called 5T4, a protein embedded within the membrane of cancer cells. The protein is rarely found in normal tissues, but is produced at high levels by a wide range of human cancers, including colorectal, renal, gastric and ovarian. The
'"/>

Contact: Greg Lester
lester@aacr.org
267-646-0554
American Association for Cancer Research
1-Aug-2007


Page: 1 2 3

Related biology news :

1. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
2. Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial
3. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
4. Phase III trials of cellulose sulfate microbicide for HIV prevention closed
5. Phylonix awarded National Science Foundation Phase II SBIR for zebrafish screening
6. Kentucky first state to match federal SBIR-STTR Phase 1 and Phase 2 grants
7. Acorda announces positive Phase 3 Fampridine-SR study in people with multiple sclerosis
8. REMICADE Phase 3 data show rapid, significant, long-term psoriasis improvement
9. New Phase 3 data show potential benefits of Aranesp dosed every three weeks for CIA
10. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
11. Centocor & Schering-Plough next generation biologic promising in Phase 2 rheumatoid arthritis trial

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/19/2019)... ... August 19, 2019 , ... ... the use of ultra-thin two dimensional slices which are placed on microscope slides, ... for complex tissues and complicated features such as vasculature and thus researchers in ...
(Date:8/15/2019)... ... August 15, 2019 , ... ... As serialization mandates become increasingly complex, and aggregation becomes fully applied in the ... is the best long-term solution. , Until now, most regulations?including the Drug Supply ...
(Date:8/14/2019)... ... August 14, 2019 , ... ... explore how developments in microbiome therapeutics are helping to promote normal immune function ... information. , Advancements will educate about the DECODE.DESIGN.CURE™ technology platform, which rapidly develops ...
Breaking Biology News(10 mins):
(Date:8/6/2019)... ... 2019 , ... Advanced Clinical, a clinical research services organization, ... PharmaVOICE magazine, earning him a prestigious spot on the 2019 PharmaVOICE 100 list. ... As the executive vice president of business development and marketing at Advanced Clinical, ...
(Date:7/26/2019)... ... July 25, 2019 , ... LeadingBiotech , an ... today announces its Boston BD conference to be held on September ... Week Boston , the event provides an opportunity for attendees to leverage insight ...
(Date:7/17/2019)... ... July 15, 2019 , ... CRISPR is often thought of as “molecular scissors” ... removed, replaced, or edited, but Yiping Qi, assistant professor in Plant Science & Landscape ... his latest publication in Nature Plants. In this comprehensive review, Qi and coauthors in ...
(Date:7/9/2019)... ... 2019 , ... Today, at the BIO World Congress on Industrial ... (NCGA) announced the winners of the Consider Corn Challenge II. Three winners were chosen, ... to produce biobased materials. , “Corn is a sustainable, abundant and affordable ...
Breaking Biology Technology:
Cached News: